- Everyday Alpha
- Posts
- SiriusPoint Is Done Cleaning House, and Now Comes the Capital
SiriusPoint Is Done Cleaning House, and Now Comes the Capital
This insurer is handing off its legacy problems and could free up over $200 million of capital.
This specialty insurer spent the past year selling assets, shedding its legacy reserves, and buying back stock, and it still trades at a single-digit multiple of earnings. A new deal announced last week could free up more than $200 million of capital heading into 2027.
14% Annualized: Meet CHAD, Nasdaq-Listed Preferred Stock
Meet CHAD (Nasdaq: CHAD), DeFi Development Corp.'s variable-rate perpetual preferred stock. CHAD currently offers a 14% annualized dividend rate, paid each business day when declared. Based on its current balance sheet, DFDV estimates more than 100 years of dividend coverage. Learn how CHAD works and see the full risk disclosures at whoischad.com.
CHAD is variable-rate preferred stock. Dividends are not guaranteed, and the dividend rate may change. Investment involves risk, including possible loss of principal. CHAD is not FDIC insured. For important risks, disclosures, and prospectus, visit whoischad.com/disclaimer.
SiriusPoint Ltd.

November 11 – Pre‑market
Ticker: SPNT (NYSE) | Sector: Financial Services (Specialty Insurance and Reinsurance) | Market Cap: $3.15B
30‑Second Take
SiriusPoint Ltd. (NYSE: SPNT) is a Bermuda-based specialty insurer and reinsurer. Alongside its third-quarter results on November 5, it agreed to a loss portfolio transfer (LPT) that hands substantially all of its remaining run-off reserves, about $400 million of net liabilities, to RiverStone International.
The company expects the deal to unlock more than $200 million of capital that currently supports that old book. It follows the sales of its ArmadaCare and Arcadian MGA stakes for a combined $389 million, and it is still subject to regulatory approval.
The question for investors is what happens to that capital. SiriusPoint has repurchased about $100 million of stock so far this year, and Oppenheimer lifted its price target to $31 from $27 on November 9 while keeping an Outperform rating.
Trade Setup
Timeframe: Swing to medium-term (three to six months)
Edge type: Balance sheet cleanup plus capital return on a low-multiple insurer
This is a bet that a simpler, better-capitalized SiriusPoint deserves a higher multiple than the market gives it today, and that freed-up capital flows back to shareholders. It is a lower-volatility setup, but catastrophe losses and softer reinsurance pricing can still hurt it.
The holiday streaming season is almost here
Are you ready? As revealed in our holiday playbook, Roku Ads Manager lets you easily set up, measure and optimize your self-serve holiday ad campaign. You can even create a shoppable ad unit that lets streamers buy directly from their remote.
Mortgage paid off by 40, or retirement maxed out every year instead? |
Snapshot Table
Metric | Value | Current Stance |
|---|---|---|
Price | #27.38 | Near its 52-week high |
52-Week Range | $19.15 to $27.12 | At the top of the range after results |
Market Cap | $3.15B | Small-cap specialty insurer |
P/E Ratio | 6.5 trailing, ~10 forward | Trailing figure includes a one-time $222M sale gain |
Avg Daily Volume | 840K shares (3-month) | Heavier in the sessions after Q3 results |
Beta | 0.6 (5-year monthly) | Moves less than the market |
Next Catalyst | RiverStone LPT regulatory approval | January 1 renewals; Q4 results expected in February |
Chart

1-Month Trading Summary: SPNT is up about 3% over the past month, grinding from the mid-$20s to a fresh 52-week high after its November 5 report and the Oppenheimer target increase.
It held up while the broader market slipped over the same stretch, and volume ran above its three-month average of about 840,000 shares a day in the sessions after results.
Bull Case
Why It Works
SiriusPoint has spent the past year turning a messy balance sheet into a simpler one. It sold its 100% stake in ArmadaCare to Ambac for $250 million in October 2025, then sold its 49% stake in Arcadian Risk Capital to Lee Equity Partners for $139 million in January 2026.
Both deals kept long-term underwriting capacity agreements in place, so SiriusPoint keeps the business flow without tying up equity.
The RiverStone LPT is the last big piece. Once approved, it closes the book on the legacy run-off reserves, and management is folding reinsurance into a new specialty P&C segment.
The Catalysts
The first catalyst is regulatory approval of the RiverStone deal, which would release the capital tied to the run-off book. The second is what management does with it.
The company had about $73.9 million left under its repurchase authorization at the end of September, and management discussed restarting buybacks on the third-quarter call.
The third is the January 1 renewal season, when the bulk of the year's reinsurance business reprices. SiriusPoint's growth is now coming mostly from its Insurance and Services business rather than property catastrophe reinsurance, so management's commentary on how it allocates capacity into 2027 is the next read on the strategy.
What The Numbers Say
Third-quarter core gross written premiums rose 14%, driven by 20% growth in Insurance and Services. The core combined ratio was 90.1%, operating return on equity was 17.6%, and diluted book value per share excluding AOCI rose 4% from June 30 to $20.21. The estimated Bermuda solvency ratio (BSCR) stood at 232%, well above regulatory requirements.
Bear Case
What Could Break It
Reinsurance pricing is softening. Property catastrophe rates fell by double digits at the January and July 2026 renewals, and J.P. Morgan said in early November that it expects those declines to persist. SiriusPoint has less property cat exposure than many peers, but softer pricing still squeezes margins across the market.
Catastrophe risk never goes away. A major hurricane, wildfire, or other large-loss event can wipe out a quarter or more of underwriting profit, and regulators could still delay or reshape the RiverStone deal.
The Valuation Risk
The headline trailing P/E of roughly 6.5 flatters the stock, because trailing earnings still include the $222 million pre-tax gain from the ArmadaCare sale.
On forward estimates the multiple is closer to 10, and the stock trades at about 1.3 times book value excluding AOCI. It is reasonably priced, not deeply discounted, so the upside depends on capital return and steady underwriting.
How To Size It
SiriusPoint does not pay a common dividend, so returns come entirely from the share price. With a beta near 0.6, it tends to move less than the market in both directions.
Start with a half position, add once the LPT clears regulators or buybacks resume, and cut it if the stock falls back below $23, which would erase its post-earnings breakout.
Quick Checklist
✅ RiverStone LPT regulatory approval
✅ Buyback activity resumes before year-end
✅ Management commentary on January 1 renewals
Deep‑Dive Links
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!
Best Regards,
—Noah Zelvis
Everyday Alpha


